SCHEMBL4485541

SCHEMBL4485541

CN(C)CCN(c1ccc(N/C(=C2\C(=O)Nc3cc(F)ccc32)c2ccccc2)cc1)S(=O)(=O)Cc1ccccc1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RORC P51449 2/20 0.37
BACE1 P56817 1/20 0.36
BRD4 O60885 5/20 0.35
FLT3 P36888 2/20 0.35
MAPT P10636 3/20 0.35
NAMPT P43490 2/20 0.35
MEN1 O00255 2/20 0.34
POLB P06746 2/20 0.34
KMT2A Q03164 2/20 0.34
PDGFRB P09619 2/20 0.34
HTT P42858 1/20 0.34
KDM4E B2RXH2 1/20 0.33
AURKA O14965 1/20 0.33
PDGFRA P16234 1/20 0.33
KDR P35968 1/20 0.33
AURKB Q96GD4 1/20 0.33
AURKC Q9UQB9 1/20 0.33
CASP3 P42574 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4485545 1.00 RORC (0.37) RORCBACE1BRD4FLT3MAPT
SCHEMBL4480741 0.93 BACE1 (0.38) BACE1BRD4FLT3MAPTMEN1
SCHEMBL4480738 0.93 BACE1 (0.38) BACE1BRD4FLT3MAPTMEN1
SCHEMBL4492981 0.91 BACE1 (0.36) BACE1BRD4FLT3MAPTMEN1
SCHEMBL4492980 0.91 BACE1 (0.36) BACE1BRD4FLT3MAPTMEN1
SCHEMBL4506037 0.91 RORC (0.37) RORCBRD4MAPTNAMPTMEN1
SCHEMBL4506035 0.91 RORC (0.37) RORCBRD4MAPTNAMPTMEN1
SCHEMBL4484967 0.91 BACE1 (0.38) BACE1BRD4FLT3MAPTMEN1
SCHEMBL4484962 0.91 BACE1 (0.38) BACE1BRD4FLT3MAPTMEN1
SCHEMBL4502856 0.90 RORC (0.37) RORCMAPTNAMPTMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 US disclosed
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-08-31 US disclosed
EP-1527046-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-05-04 EP disclosed
WO-2004009546-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions KDR, FLT1, EGFR RORC 309/4885BACE1 1615/4885BRD4 2704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.